Stocks · News reference
Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline
Statistically significant reduction in acute pancreatitis events versus placebo across the entire sHTG study population, with an unprecedented 100% event reduction in high-risk patientsContinued and consistent safety
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 22, 2026, 11:32 AM
- Checked
- Jul 22, 2026, 11:32 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome
REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical
Read original at benzingaHC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.
Read original at benzingaArrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from
Read original at benzinga